Papillary and neuroendocrine breast lesions: the <scp>WHO</scp> stance

Tan, Puay Hoon; Schnitt, Stuart J.; Vijver, Marc J. van de; Ellis, Ian O.; Lakhani, Sunil R.

doi:10.1111/his.12463

Cited by 118 publications

(111 citation statements)

References 44 publications

(86 reference statements)

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Poorly differentiated/ small-cell neuroendocrine carcinomas are morphologically identical to small-cell lung cancer, with a high nuclear/ cytoplasmic ratio, dense chromatin, a brisk mitotic rate, and areas of necrosis. The third group comprises several morphologic subtypes of invasive breast carcinoma with neuroendocrine differentiation, mainly represented by the hypercellular variant of mucinous carcinoma and the invasive form of solid papillary carcinoma [13].…”

Section: Pathological Classificationmentioning

confidence: 99%

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

et al. 2015

View full text Add to dashboard Cite

Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline-and taxane-based regimens represent the most frequently administered chemotherapy in neoadjuvant and adjuvant setting, as well as for metastatic disease, although combinations of platinum compounds and etoposide have been widely used, in particular for small-cell histology and tumors with a high proliferation index. For metastatic disease, a multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination of the above. In the near future, a better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment. In this review, we discuss the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast. The Oncologist 2016;21:28-32 Implications for Practice: Neuroendocrine carcinoma of the breast (NECB) is a distinct entity of breast cancer. Clinical features and morphology are not helpful to distinguish NECB from other subtypes of breast cancer; therefore, immunohistochemistry markers for neuroendocrine differentiation, mainly chromogranin and synaptophysin, should be routinely used to confirm the diagnosis, especially in cases of mucinous or solid papillary carcinoma in which the suspicion of NECB may be relevant. Adjuvant treatment should be offered according to the same recommendations given for the other types of invasive breast cancer. An accurate diagnosis of NECB is also important in the metastatic setting, in which a multimodality approach including specific therapies such as peptide receptor radionuclide therapy can be considered.

show abstract

Section: Pathological Classificationmentioning

confidence: 99%

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

et al. 2015

View full text Add to dashboard Cite

show abstract

“…1d). The final diagnosis was borderline PT, according to the WHO classification [5], of the right breast, with incomplete excision. The patient underwent new surgery for complete removing of the tumour and has been without relapse for the last 6 months.…”

Section: Casementioning

confidence: 99%

Stromal Cellular Fragments in Breast Fine Needle Aspirates: Think Outside of the Box

Oliveira

Schmitt

2018

Acta Cytologica

View full text Add to dashboard Cite

Background: The presence of highly cellular stromal fragments in breast fine needle aspirates (FNA) suggests some classical differential diagnoses such as cellular fibroadenoma, phyllodes tumour (PT), metaplastic carcinomas, and some mesenchymal/myoepithelial proliferations. The other components of the smears can help in the differential diagnosis, but the presence of a low-grade epithelial proliferation does not always represent a fibro-epithelial lesion as we demonstrate in these two cases. Cases: We discuss two cases of breast FNA, previously presented in a slide seminar at the 29th European Congress of Pathology in Amsterdam, where the common cytological finding was the presence of stromal cellular fragments together with an epithelial component. One case is a typical PT and the other is a case of a mammary carcinoma with osteoclast-like giant cells. Conclusion: Mammary carcinoma with osteoclast-like giant cells is an unusual type of breast carcinoma that should be included in the differential diagnosis of breast lesions containing cellular stroma. Since the associated carcinoma is usually low grade, careful evaluation for malignant cells on cytological smears is necessary for an accurate differential diagnosis with PT where the epithelial component is benign.

show abstract

“…SPC is an uncommon neoplasm of the breast and accounts for <1% of all breast carcinomas [15-17]. It shows a distinct morphology, and is divided into DCIS and invasive subtypes.…”

Section: Introductionmentioning

confidence: 99%

Histopathology and Cytopathology of Neuroendocrine Tumors and Carcinomas of the Breast: A Review

et al. 2019

View full text Add to dashboard Cite

Neuroendocrine tumors (NET) and carcinomas (NEC) of the breast are rare diseases, but NEC has attracted attention in both cytopathology and surgical pathology because of its specific management and prognosis. Fine-needle aspiration biopsy (FNAB) cytology can make the diagnosis in many cases particularly with high-grade NEC, with definitive diagnosis based on histopathology and immunohistochemistry. This review describes the characteristics of the disease based on the WHO classification 2012 and recent literature and includes discussion related to the International Academy of Cytology Yokohama System of Reporting Breast FNAB cytology.

show abstract

Papillary and neuroendocrine breast lesions: the WHO stance

Cited by 118 publications

References 44 publications

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

Stromal Cellular Fragments in Breast Fine Needle Aspirates: Think Outside of the Box

Histopathology and Cytopathology of Neuroendocrine Tumors and Carcinomas of the Breast: A Review

Contact Info

Product

Resources

About